CARGO Therapeutics, Inc. (CRGX) was downgraded to a Hold Rating at William Blair
CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The ...
Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
The American Journal of Managed Care1d
EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
precisionmedicineonline1d
Sarepta's DMD Gene Therapy Elevidys Shows Sustained Benefits in Updated Phase III Data
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
PMLiVE1d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Sarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial Outlook
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...
Roche reports positive topline outcomes from DMD treatment trial
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...
ENDPOINTS NEWS2d
Sarep­ta shares two-year DMD study da­ta that could in­form Eu­ro­pean ap­proval de­ci­sion
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...
Mizuho maintains Sarepta stock with $195 target on trial data
Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...
EuropaWire2d
Roche Reports Sustained Two-Year Improvements with Elevidys Gene Therapy for Duchenne Muscular Dystrophy
Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approv ...
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...